Related Experiment Video
Updated: Jun 3, 2025
07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
3.5K
Seltorexant for major depressive disorder.
Kyle Valentino1,2,3, Kayla M Teopiz1, Sabrina Wong1,2,3
1Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Expert Opinion on Emerging Drugs
|January 10, 2025
Summary
Seltorexant, an orexin receptor antagonist, shows promise for treating Major Depressive Disorder (MDD), particularly in patients with severe sleep disturbances. Further Phase III trials are required to confirm its efficacy and safety for depression treatment.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Orexin systems are implicated in regulating sleep-wake cycles, reward, and cognition, suggesting therapeutic potential for mental disorders.
- Existing treatments for Major Depressive Disorder (MDD) have limitations in efficacy and tolerability, necessitating novel therapeutic approaches.
- Seltorexant, an orexin receptor antagonist, is an investigational compound targeting these pathways for potential MDD treatment.
Purpose of the Study:
- To review the role of orexin systems in MDD, focusing on sleep and reward mechanisms.
- To evaluate the safety, tolerability, and efficacy of seltorexant as a novel therapeutic for MDD.
- To discuss the broader implications of orexin receptor antagonism in depression treatment.
Main Methods:
- Systematic literature search of PubMed, Medline, Cochrane Library, Embase, Scopus, and Web of Science from inception to October 10, 2024.
- Review of preclinical and clinical data on seltorexant and orexin receptor antagonism.
- Analysis of mechanisms implicated in MDD, including reward and sleep.
Main Results:
- Early clinical evidence indicates seltorexant is effective in treating MDD.
- Antidepressant effects are more pronounced in MDD patients with severe sleep disturbances.
- Seltorexant demonstrates efficacy in both individuals with and without comorbid insomnia.
Conclusions:
- Seltorexant represents a potential novel therapeutic for MDD by targeting the orexin system.
- The drug shows particular promise for patients experiencing significant sleep disturbances alongside depression.
- Confirmation of seltorexant's efficacy and safety in large-scale Phase III clinical trials is essential.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
192
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
192
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
299
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
299
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
145
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
145
01:25Antidepressant Drugs: Overview
356
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
356
01:17Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146